ECSP088635A - Formulaciones orales que comprenden tigeciclina - Google Patents

Formulaciones orales que comprenden tigeciclina

Info

Publication number
ECSP088635A
ECSP088635A EC2008008635A ECSP088635A ECSP088635A EC SP088635 A ECSP088635 A EC SP088635A EC 2008008635 A EC2008008635 A EC 2008008635A EC SP088635 A ECSP088635 A EC SP088635A EC SP088635 A ECSP088635 A EC SP088635A
Authority
EC
Ecuador
Prior art keywords
tigecicline
oral formulations
tigecyclines
composition
pharmaceutical compositions
Prior art date
Application number
EC2008008635A
Other languages
English (en)
Inventor
Syed M Shah
Christopher Richard Diorio
Kadum A Ali
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088635A publication Critical patent/ECSP088635A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen en la presente composiciones farmacéuticas que comprenden tigeciclinas para la administración oral. La composición puede comprender tigeciclina que tiene por lo menos un revestimiento entérico.
EC2008008635A 2005-12-22 2008-07-18 Formulaciones orales que comprenden tigeciclina ECSP088635A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75303505P 2005-12-22 2005-12-22

Publications (1)

Publication Number Publication Date
ECSP088635A true ECSP088635A (es) 2008-08-29

Family

ID=37964562

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008635A ECSP088635A (es) 2005-12-22 2008-07-18 Formulaciones orales que comprenden tigeciclina

Country Status (14)

Country Link
US (1) US20080014256A1 (es)
EP (1) EP1965770A2 (es)
KR (1) KR20080080205A (es)
CN (1) CN101340895A (es)
AU (1) AU2006331688A1 (es)
BR (1) BRPI0620646A2 (es)
CA (1) CA2632213A1 (es)
CR (1) CR10124A (es)
EC (1) ECSP088635A (es)
GT (1) GT200800107A (es)
IL (1) IL191789A0 (es)
NO (1) NO20082547L (es)
RU (1) RU2008120672A (es)
WO (1) WO2007075794A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9107929B2 (en) 2008-05-01 2015-08-18 Ranbaxy Laboratories Limited Stable parenteral formulations of tigecycline
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
NZ599762A (en) 2009-11-09 2014-07-25 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
JP6025712B2 (ja) 2010-05-12 2016-11-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド テトラサイクリン組成物
JP6910950B2 (ja) * 2015-01-12 2021-07-28 エンテリス・バイオファーマ・インコーポレイテッドＥｎｔｅｒｉｓ Ｂｉｏｐｈａｒｍａ，Ｉｎｃ． 固形経口剤形
WO2019139877A1 (en) * 2018-01-10 2019-07-18 The University Of North Carolina At Chapel Hill Tigecycline for topical treatment of root canal space
CN111166729A (zh) * 2020-03-19 2020-05-19 珠海赛隆药业股份有限公司 一种口服的替加环素肠溶微球及其制备方法
CN112577917A (zh) * 2020-12-28 2021-03-30 瀚晖制药有限公司 注射用替加环素中有色杂质的检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026248A (en) * 1959-09-11 1962-03-20 Pfizer & Co C Thioglycerol and formaldehyde sulfoxylate stabilized tetracycline antibiotics in polyhydric alcohol solvents
US3219529A (en) * 1962-10-04 1965-11-23 American Cyanamid Co Stable tetracycline solutions
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US5281628A (en) * 1991-10-04 1994-01-25 American Cyanamid Company 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
US5494903A (en) * 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
US5420272A (en) * 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5328902A (en) * 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
SG47520A1 (en) * 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
AU1279095A (en) * 1994-02-17 1995-09-04 Pfizer Inc. 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5567693A (en) * 1994-12-13 1996-10-22 American Cyanamid Company Method for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US6063775A (en) * 1997-04-29 2000-05-16 Berman; Charles L. Retardation of metalloproteinase incidental to HIV and/or AIDS
US5908838A (en) * 1998-02-19 1999-06-01 Medics Pharmaceutical Corporation Method for the treatment of acne
US6015803A (en) * 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6015804A (en) * 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
US6506740B1 (en) * 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
WO2001074761A1 (en) * 2000-03-31 2001-10-11 Trustees Of Tufts College 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds
SI1301467T1 (sl) * 2000-07-07 2007-02-28 Tufts College 9-substituirane minociklinske spojine
IL153672A0 (en) * 2000-07-07 2003-07-06 Tufts College 7-substituted tetracycline compounds
EP1368305B1 (en) * 2001-03-13 2008-08-13 Paratek Pharmaceuticals, Inc. 7, 9-substituted tetracycline compounds
CA2457234A1 (en) * 2001-03-14 2002-09-19 Mark L. Nelson Substituted tetracycline compounds as antifungal agents
JP2004537544A (ja) * 2001-07-13 2004-12-16 パラテック ファーマシューティカルズ インコーポレイテッド 標的治療活性を有するテトラサイクリン化合物
ES2551708T3 (es) * 2002-01-08 2015-11-23 Paratek Pharmaceuticals, Inc. Compuestos de 4-desdimetilamino tetraciclina
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
EA200900540A1 (ru) * 2002-07-12 2009-12-30 Пэрэтек Фамэсьютикэлс, Инк. Замещённые соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
AU2003274927A1 (en) * 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
ES2339003T3 (es) * 2002-08-29 2010-05-14 Activbiotics Pharma Llc Rifalazil para tratar infecciones por clostridium difficile.
US20050148553A1 (en) * 2003-09-05 2005-07-07 Testa Raymond T. Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis
GB2414668B (en) * 2004-06-03 2009-07-29 Dexcel Ltd Tetracycline modified release delivery system

Also Published As

Publication number Publication date
IL191789A0 (en) 2008-12-29
RU2008120672A (ru) 2010-01-27
BRPI0620646A2 (pt) 2011-11-22
WO2007075794A2 (en) 2007-07-05
NO20082547L (no) 2008-09-22
EP1965770A2 (en) 2008-09-10
WO2007075794A3 (en) 2007-08-16
KR20080080205A (ko) 2008-09-02
US20080014256A1 (en) 2008-01-17
CA2632213A1 (en) 2007-07-05
CN101340895A (zh) 2009-01-07
GT200800107A (es) 2008-11-19
AU2006331688A1 (en) 2007-07-05
CR10124A (es) 2008-09-23

Similar Documents

Publication Publication Date Title
CR10124A (es) Formulaciones orales que comprenden tigeciclina
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
LTC1608344I2 (lt) Per burną vartojamos kladribino kompozicijos
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
BRPI0710508B8 (pt) composição de pepticorpo terapêutico liofilizado estável, kit para preparar uma composição farmacêutica aquosa, e métodos para fabricar um pepticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico reconstituído
NO20092611L (no) Krystallinsk faststoff Rasagilin base
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
BRPI0509184A (pt) composições farmacêuticas
NO20052306D0 (no) Dispergerbare farmasoytiske blandinger.
CU23616B7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CU23615B7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CY1109465T1 (el) Νεες φαρμακευτικες φαρμακοτεχνικες μορφες μονταφινιλης
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
HN2009000566A (es) Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen.
BRPI0408895A (pt) formulações de cladribina para administração oral e transmucosal aperfeiçoada
DOP2006000268A (es) Agentes antibacterianos
BRPI0606687A2 (pt) composições nutracêuticas
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
PA8781501A1 (es) Formulacion de pasireotida
BRPI0620229A8 (pt) formulação
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
ATE429906T1 (de) Trockene aripiprazolformulierungen
ATE552832T1 (de) Antidepressivum-propharmaka
CL2007003847A1 (es) Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина